AbbVie (MEX:ABBV) Shiller PE Ratio: (As of Sep. 22, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MEX:ABBV AbbVie Inc MEX:ABBV
70 GF Score
Price MXN4,564.00
GF Value MXN3,770.36
Valuation Modestly Overvalued
! 5 Warning Signs
View Full Analysis

What is AbbVie Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


AbbVie  (MEX:ABBV) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


AbbVie Shiller PE Ratio Related Terms


AbbVie Shiller PE Ratio Historical Data

* Premium members only.

The historical data trend for AbbVie's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

AbbVie Shiller PE Ratio Chart

AbbVie Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 39.97 39.13 30.60 40.09 45.45

AbbVie Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 38.45 46.27 45.35 41.36 47.41

MEX:ABBV vs MRK, JNJ, AMGN: Shiller PE Ratio Comparison

For the Drug Manufacturers - General subindustry, AbbVie's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


AbbVie Shiller PE Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, AbbVie's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where AbbVie's Shiller PE Ratio falls into.


MEX:ABBV
70GF Score
AbbVie Inc MEX:ABBV
Shiller PE Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

AbbVie Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

AbbVie's E10 for the quarter that ended in Jun. 2026 is calculated as:

For example, AbbVie's adjusted earnings per share data for the three months ended in Jun. 2026 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=35.3698/333.9520*333.9520
=35.370

Current CPI (Jun. 2026) = 333.9520.

AbbVie Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201609 18.194 241.428 25.166
201612 16.865 241.432 23.328
201703 21.520 243.801 29.478
201706 22.075 244.955 30.095
201709 18.011 246.819 24.370
201712 0.569 246.524 0.770
201803 32.592 249.554 43.614
201806 24.450 251.989 32.402
201809 34.356 252.439 45.449
201812 -24.383 251.233 -32.411
201903 31.683 254.202 41.623
201906 9.372 256.143 12.219
201909 24.554 256.759 31.936
201912 36.146 256.974 46.974
202003 40.469 258.115 52.359
202006 -10.708 257.797 -13.871
202009 28.546 260.280 36.626
202012 0.232 260.474 0.297
202103 40.473 264.877 51.027
202106 8.444 271.696 10.379
202109 35.597 274.310 43.337
202112 46.967 278.802 56.258
202203 51.529 287.504 59.854
202206 10.308 296.311 11.618
202209 44.808 296.808 50.415
202212 27.385 296.797 30.813
202303 2.395 301.836 2.650
202306 20.118 305.109 22.020
202309 17.027 307.789 18.474
202312 8.038 306.746 8.751
202403 13.025 312.332 13.927
202406 13.241 314.175 14.075
202409 16.569 315.301 17.549
202412 -0.364 315.605 -0.385
202503 14.697 319.799 15.347
202506 10.232 322.561 10.593
202509 1.851 324.800 1.903
202512 18.633 324.054 19.202
202603 6.780 330.213 6.857
202606 35.370 333.952 35.370

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

Is AbbVie (MEX:ABBV) Overvalued in 2026?

Based on GuruFocus' analysis, AbbVie stock appears to be overvalued. The current stock price of MXN4,564.00 is trading 21% above its estimated GF Value™ of MXN3,770.36. GuruFocus considers AbbVie to be Modestly Overvalued.

Key valuation signals for MEX:ABBV:

  • Shiller PE Ratio:
  • GF Value™: MXN3,770.36 vs. price of MXN4,564.00 (21% above fair value)
  • GF Score™: 70/100 with 5 warning signs

No single metric tells the full story. See the MEX:ABBV stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


AbbVie Business Description

Address 1 North Waukegan Road, North Chicago, IL, USA, 60064-6400
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio.
70GF Score

Get the complete analysis for MEX:ABBV

Shiller PE Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN4,564.00
Price
MXN3,770.36
GF Value